Pacific Biosciences of California (NASDAQ:PACB) Issues Earnings Results

Pacific Biosciences of California (NASDAQ:PACB) posted its earnings results on Thursday. The biotechnology company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.04), Fidelity Earnings reports. Pacific Biosciences of California had a negative net margin of 140.68% and a negative return on equity of 106.36%. The business had revenue of $21.92 million during the quarter, compared to analysts’ expectations of $28.02 million.

Shares of PACB stock traded down $0.18 on Friday, hitting $4.69. The stock had a trading volume of 2,543,200 shares, compared to its average volume of 1,647,294. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.00 and a quick ratio of 1.65. The firm has a market capitalization of $743.41 million, a P/E ratio of -6.17 and a beta of 1.68. Pacific Biosciences of California has a 1 year low of $4.37 and a 1 year high of $7.84. The company’s 50 day moving average price is $5.11 and its 200-day moving average price is $5.96.

A number of research firms have commented on PACB. BidaskClub downgraded Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 29th. ValuEngine upgraded Pacific Biosciences of California from a “sell” rating to a “hold” rating in a research report on Monday. Finally, Piper Jaffray Companies upgraded Pacific Biosciences of California from a “neutral” rating to an “overweight” rating and set a $8.00 target price on the stock in a research report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $8.00.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

Further Reading: How to trade on quiet period expirations

Earnings History for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply